Population Pharmacokinetics Analysis of Mycophenolic Acid in Adult Kidney Transplant Patients With Chronic Graft Dysfunction

The aim of this study is to develop a population pharmacokinetic model for total and free mycophenolic acid (MPA) in adult kidney transplant patients with chronic graft dysfunction to understand the contribution of potentially relevant covariates to the inter- and the intraindividual variability of MPA in these patients. Twenty patients received mycophenolate mofetil orally up to 1 g twice daily were enrolled in this prospective pharmacokinetic study. Two hundred twenty-nine total and 257 free concentration-time points were determined using reversed-phase high-performance liquid chromatography/ultraviolet at 21 days and 6 months after initiation of mycophenolate mofetil therapy. Data were analyzed using nonlinear mixed effects modeling. A two-compartment model, with zero-order input and first-order elimination from the central compartment, which combined total and free concentration, was selected. Intersubject variability (ISV) was estimated on the clearance, central volume of distribution, and intercompartmental clearance. Only body weight (WT, kg), occasion, and albumin concentration (mg/L) were kept as covariates in the final model. The population pharmacokinetic parameters were: clearance, 0.27 × WT (L/h) on Day 21 and 0.233 × WT (L/h) at 6 months (ISV, 51%; interoccasion variability, 47%); central distribution volume, 47.6 L (ISV, 31%); intercompartmental clearance, 33.1 L/h (ISV, 128%); peripheral distribution volume, 724 L; duration of infusion, 0.64 (hours), and binding capacity, 0.0012 L/mg. The multiple regression analysis between free and total MPA concentration led to the following model: free MPA concentration (mg/L) = 0.31 + 0.02 total MPA concentration (mg/L) - 0.007 albumin (g/L). The large inter- and intravariability of MPA raises questions about the value of the use of therapeutic monitoring and limited sampling strategies as currently practiced. Moreover, none of the data presented here could justify measurement of free concentration for therapeutic drug monitoring.

[1]  L. Shaw,et al.  The Effect of Renal Insufficiency on Mycophenolic Acid Protein Binding , 1999, Journal of clinical pharmacology.

[2]  L. Shaw,et al.  Pharmacokinetics of mycophenolic acid in renal insufficiency. , 2000, Therapeutic drug monitoring.

[3]  P. Marquet,et al.  Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Concentrations in Stable Renal Transplant Patients , 2004, Clinical pharmacokinetics.

[4]  L. Shaw,et al.  Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. , 2000, Therapeutic drug monitoring.

[5]  Mats O. Karlsson,et al.  Assumption Testing in Population Pharmacokinetic Models: Illustrated with an Analysis of Moxonidine Data from Congestive Heart Failure Patients , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[6]  F. González-Roncero,et al.  Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. , 2005, Transplantation proceedings.

[7]  M. Hale,et al.  Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous Administration , 1996, Journal of clinical pharmacology.

[8]  A. Nicholls,et al.  Clinical Pharmacokinetics of Mycophenolate Mofetil , 1998, Clinical pharmacokinetics.

[9]  D. Hesselink,et al.  Individualization of mycophenolate mofetil dose in renal transplant recipients. , 2006, Expert opinion on pharmacotherapy.

[10]  A. Vulto,et al.  Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Recipients , 2005, Clinical pharmacokinetics.

[11]  L. Shaw,et al.  Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. , 1998, Clinical chemistry.

[12]  B. Kiberd,et al.  Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation , 2005, European Journal of Clinical Pharmacology.

[13]  D. Hesselink,et al.  Individualisation of mycophenolate mofetil dose in renal transplant recipients , 2006 .

[14]  S. Swan,et al.  The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function , 1998, Clinical pharmacology and therapeutics.

[15]  M. Durlik,et al.  Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post‐transplant , 2006, Journal of clinical pharmacy and therapeutics.

[16]  S. Tett,et al.  Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. , 2003, British journal of clinical pharmacology.

[17]  C. Davis,et al.  Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. , 2000, Kidney international.

[18]  L. Shaw,et al.  Pharmacokinetic Modelling of the Plasma Protein Binding of Mycophenolic Acid in Renal Transplant Recipients , 2009, Clinical pharmacokinetics.

[19]  L. Shaw,et al.  Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. , 1995, Clinical chemistry.

[20]  L. Shaw,et al.  Pharmacokinetics of Mycophenolic Acid in Renal Transplant Patients with Delayed Graft Function , 1998, Journal of clinical pharmacology.

[21]  D. Kuypers,et al.  The Impact of Renal Allograft Function on Exposure and Elimination of Mycophenolic Acid (MPA) and Its Metabolite MPA 7-O-glucuronide , 2007, Transplantation.

[22]  J. Ransom.  Mechanism of Action of Mycophenolate Mofetil , 1995, Therapeutic drug monitoring.

[23]  L. Weber,et al.  Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. , 1998, Journal of the American Society of Nephrology : JASN.

[24]  David W. Johnson,et al.  Free Mycophenolic Acid Should Be Monitored in Renal Transplant Recipients with Hypoalbuminemia , 2004, Therapeutic drug monitoring.